Loading…
← CockpitCompetitor Analysis › 000766.SZ Tonghua Golden-Horse Pharmaceutical Industry Co. Ltd. Class AOpen in the cockpit ↗

Tonghua Golden-Horse Pharmaceutical Industry Co. Ltd. Class A000766.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Jilin-based Chinese pharmaceutical company; specific product lines not fully confirmed from available knowledge.

Momentum laggard 10
Mkt cap
$1.62B
US dollars, full cap
Free float
51%
of shares outstanding
$/day
$37.1M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-2.7 pp
WACC 5.3%
Hurdle
+32 pp
Req g minus delivered
Close · CNYCN¥12.03
1D-10.0%
1W-17.9%
1M-17.6%
3M-29.5%
6M-47.3%
YTD-56.2%
1Y-57.0%
ATR %7.0%
52w lowhigh60.2% off high

What Tonghua Golden-Horse Pharmaceutical Industry does

Jilin-based Chinese pharmaceutical company; specific product lines not fully confirmed from available knowledge.

Where it sits in the supply chain

  • Health Care
  • Pharmaceuticals

Moat: none

Headquarters: Tonghua, Jilin, China · Employees: 1,480

Tonghua Golden-Horse Pharmaceutical Industry at a glance

Size Tonghua Golden-Horse Pharmaceutical Industry (000766.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.62B, the 1414th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.03 on 18 Nov 2026.

Performance Over six months the shares fell 47.3%, against -3.7% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 20 in its peer set.

Growth Revenue fell 17.9% over the last twelve months (peer median +6.8%); the operating margin is 8.6% (peer median 12.0%).

Valuation It trades at 12.2× enterprise value to sales against a peer median of 4.5× (3rd most expensive of 20).

Price implies For today's price to make sense, revenue must grow about 33% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is +32 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.7 points below its cost of capital (5.3% WACC).

Relative performance

608010012021 May 202621 Aug 202618 Nov 2026Peer median 96000766.SZ 53
Six months, rebased to 100: Tonghua Golden-Horse Pharmaceutical Industry against the median of its 20 peers (local-currency closes).

Tonghua Golden-Horse Pharmaceutical Industry financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.01BCN¥1.16BCN¥1.31BCN¥1.47BCN¥1.46B
Revenue growth—-12%-11%0%—
Gross profitCN¥763MCN¥802MCN¥948MCN¥1.06BCN¥1.08B
EBITDAn/aCN¥172MCN¥203MCN¥199MCN¥189M
Net incomeCN¥11.3MCN¥34.3MCN¥56.4MCN¥43.9MCN¥30.2M
Free cash flowCN¥52.0MCN¥41.0MCN¥114MCN¥86.1MCN¥174M
Capital expenditureCN¥38.1MCN¥64.1MCN¥49.2MCN¥26.7MCN¥23.7M
Total debtCN¥2.03BCN¥1.81BCN¥1.80BCN¥1.71BCN¥1.80B

Quarterly statements and history in the cockpit →

Tonghua Golden-Horse Pharmaceutical Industry competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%+20%-20%0%+20%ASTRAZENANURAS3010470027556004201681JUBLPHARMA002675002019300357SRPTINDGN600993CAPLIPOINT300723FAEMAZE688166600572000766.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Tonghua Golden-Horse Pharmaceutical Industry is the large dot.

Fundamentals: revenue growth against valuation

-100%-50%0%0×20×40×60×ASTRAZENANURAS3010470027556004201681002019300357INDGN300723MAZE000766.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Tonghua Golden-Horse Pharmaceutical Industry is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%ASTRAZEN3010470027556004201681002675300357SRPTINDGN600993CAPLIPOINT300723FAE688166600572000766.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Tonghua Golden-Horse Pharmaceutical Industry is the large dot.

Tonghua Golden-Horse Pharmaceutical Industry competitors and peer comparison

How Tonghua Golden-Horse Pharmaceutical Industry compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Tonghua Golden-Horse Pharmaceutical Industry against its 20 peers (data as of 18 Nov 2026)
Measure000766.SZPeer medianRank in peer set
1-month return-17.6%-3.8%3rd lowest of 21
6-month return-47.3%-3.7%2nd lowest of 20
Distance from 52-week high-60.2%-33.2%2nd lowest of 21
Revenue growth (TTM)-17.9%+6.8%4th lowest of 20
Operating margin8.6%12.0%8th lowest of 20
EV / Sales12.2×4.5×3rd most expensive of 20
Growth the price implies (Req g, 7 yrs)33.0%11.3%3rd most demanding of 16
Growth delivered (Del g)+0.9%+9.2%6th lowest of 16
Hurdle (Req g minus delivered)+32.0 pp+7.6 pp2nd most demanding of 16
ROIC minus cost of capital-2.7 pp+0.6 pp9th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Tonghua Golden-Horse Pharmaceutical Industry 000766.SZChina$1.62B-47%-18%9%12.2×33.0%+0.9%
AstraZeneca Pharma India ASTRAZEN.NSIndia$1.62B-30%+30%10%5.6×42.4%+23.0%
Anupam Rasayan India ANURAS.NSIndia$1.61B-3%+24%16%7.2×n/an/a
Sino Biological 301047.SZChina$1.60B+27%+20%17%9.8×31.1%-15.1%
Beijing Aosaikang Pharmaceutical 002755.SZChina$1.60B-31%-13%12%5.2×12.8%-14.0%
Shanghai Shyndec Pharmaceutical 600420.SSChina$1.59B-14%-13%6%1.2×-6.6%-5.6%
Consun Pharmaceutical 1681.HKHong Kong$1.65B+8%+15%35%2.2×-14.9%+13.5%
Jubilant Pharmova JUBLPHARMA.NSIndia$1.59B-8%+18%7%2.0×n/an/a
Yantai Dongcheng Biochemicals 002675.SZChina$1.59B0%-4%15%4.5×6.0%-4.3%
Braveheart Bio BRVEUnited States$1.67Bn/an/an/an/an/an/a
Yifan Pharmaceutical 002019.SZChina$1.57B-19%-5%8%2.5×n/an/a
Zhejiang Wolwo Bio-Pharmaceutical 300357.SZChina$1.67B-12%+7%39%8.9×18.4%+10.8%
Sarepta Therapeutics SRPTUnited States$1.56B-15%-19%0%0.9×-6.8%+32.4%
Indegene INDGN.NSIndia$1.69B+28%+36%12%3.6×31.4%+29.4%
Mayinglong Pharmaceutical 600993.SSChina$1.70B+2%+7%17%2.3×-3.5%+6.8%
Caplin Point Laboratories CAPLIPOINT.NSIndia$1.70B+2%+17%31%6.3×24.3%+15.7%
ApicHope Pharmaceutical 300723.SZChina$1.70B-36%-28%-50%16.7×11.3%-11.0%
Faes Farma FAE.MCSpain$1.71B+6%+32%14%2.6×3.7%+9.9%
Maze Therapeutics MAZEUnited States$1.71B+27%-100%-821%68.8×n/an/a
BrightGene Bio-Medical Technology 688166.SSChina$1.71B-57%+14%7%9.7×35.3%+9.2%
Zhejiang CONBA Pharmaceutical 600572.SSChina$1.52B-4%+4%9%1.4×-6.1%+1.9%

Questions

Which companies are Tonghua Golden-Horse Pharmaceutical Industry's closest peers?
The cockpit's peer set: AstraZeneca Pharma India (ASTRAZEN.NS), Anupam Rasayan India (ANURAS.NS), Sino Biological (301047.SZ), Beijing Aosaikang Pharmaceutical (002755.SZ), Shanghai Shyndec Pharmaceutical (600420.SS), Consun Pharmaceutical (1681.HK), Jubilant Pharmova (JUBLPHARMA.NS), Yantai Dongcheng Biochemicals (002675.SZ).
Is Tonghua Golden-Horse Pharmaceutical Industry expensive compared with its peers?
On ev / sales it trades at 12.2× against a peer median of 4.5×, 3rd most expensive of 20 in its peer set. For today's price to make sense, revenue must grow about 33% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is +32 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Tonghua Golden-Horse Pharmaceutical Industry stock performed?
Over six months to 18 Nov 2026 the shares returned -47.3% against -3.7% for the median peer; over one year -57.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.